Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;28(10):2034-2043.
doi: 10.1038/s41593-025-02039-5. Epub 2025 Aug 11.

Aberrant splicing exonizes C9orf72 repeat expansion in ALS/FTD

Affiliations

Aberrant splicing exonizes C9orf72 repeat expansion in ALS/FTD

Suzhou Yang et al. Nat Neurosci. 2025 Oct.

Abstract

A nucleotide repeat expansion (NRE) (GGGGCC)n within the first annotated intron of the C9orf72 (C9) gene is a common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). While previous studies have shown that C9 NRE produces several toxic dipeptide repeat (DPR) proteins, the mechanism by which an intronic RNA segment can access the cytoplasmic translation machinery remains unclear. By selectively capturing and sequencing NRE-containing RNAs (NRE-capture-seq) from patient-derived fibroblasts and neurons, we found that, in contrast to previous models, C9 NRE is retained as part of an extended exon 1 due to the usage of various downstream alternative 5' splice sites. These aberrant splice isoforms accumulate in C9-ALS/FTD brains, and their production is promoted by serine/arginine-rich splicing factor 1 (SRSF1). Antisense oligonucleotides targeting either SRSF1 or the aberrant C9 splice isoforms reduced the levels of DPR. Together, our findings revealed a crucial role of aberrant splicing in the biogenesis of NRE-containing RNAs and demonstrated potential therapeutic strategies to target these pathogenic transcripts.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Yale University has filed a patent application based on this work. J.U.G. is a consultant for Corsalex, which was not involved in this project. The other authors declare no competing interests.

Update of

References

    1. Depienne, C. & Mandel, J. L. 30 years of repeat expansion disorders: what have we learned and what are the remaining challenges? Am. J. Hum. Genet. 108, 764–785 (2021). - PubMed - PMC - DOI
    1. Paulson, H. Repeat expansion diseases. Handb. Clin. Neurol. 147, 105–123 (2018). - PubMed - PMC - DOI
    1. Malik, I., Kelley, C. P., Wang, E. T. & Todd, P. K. Molecular mechanisms underlying nucleotide repeat expansion disorders. Nat. Rev. Mol. Cell Biol. 22, 589–607 (2021). - PubMed - PMC - DOI
    1. Bunting, E. L., Hamilton, J. & Tabrizi, S. J. Polyglutamine diseases. Curr. Opin. Neurobiol. 72, 39–47 (2022). - PubMed - DOI
    1. Mohan, A., Goodwin, M. & Swanson, M. S. RNA–protein interactions in unstable microsatellite diseases. Brain Res. 1584, 3–14 (2014). - PubMed - DOI

MeSH terms